Insulin-like growth factor I (IGF I) is an important mitogen for vascular smooth muscle cells. To characterize regulation of vascular IGF I receptors, we performed radioligand displacement experiments using rat aortic smooth muscle cells (RASMs) 
A variety of peptidic growth factors have been shown to be important mitogens for vascular smooth muscle cells (VSMCs) in culture. These include competence growth factors such as plateletderived growth factor (PDGF) and fibroblast growth factor (FGF) and progression factors such as insulinlike growth factor I (IGF I). Studies in BALB/c3T3 fibroblasts have clearly shown that competence factors stimulate entry of cells into the G1 phase of the cell cycle'; however, progression through S phase and subsequent cellular division requires the presence of progression factors, of which IGF I is the most potent.2 The unique role of IGF I in the control of VSMC growth has been demonstrated by Clemmons,3 most notably in experiments using an anti-IGF I antibody to inhibit PDGF-induced VSMC DNA synthesis.4 This group has demonstrated that PDGF may stimulate immunoreactive IGF I release from VSMCs,5 and we have shown that this effect occurs at the mRNA level. 6 Because VSMCs synthesize and secrete IGF I,7 this mitogen may then function in an autocrine/paracrine manner in addition to its role as a circulating growth factor. Other potentially important mitogens for VSMCs include the potent vasoactive agonist angiotensin II (Ang II). 8 We have previously shown that Ang II also regulates IGF I mRNA levels and IGF I release from quiescent VSMCs in vitro.9 Thus, both PDGF and Ang II regulate VSMC IGF I expression.
IGF I mediates its effects after binding to a specific heterotetrameric cell-surface receptor that possesses intrinsic tyrosine kinase activity.'0 Prior data have demonstrated that PDGF and FGF exposure increases "'I-IGF I binding to VSMCs.1" The main purpose of this study was to characterize regulation of VSMC IGF I receptors by growth factors. Furthermore Binding assays were performed by incubating 100 gl cell suspension with 100 ,ul binding buffer containing 10`10 M 125I-IGF I (2,300-3,100 Ci/mmol) and increasing concentrations of unlabeled IGF 1 (0-2x 10`M) for 90 minutes at 20°C. On-rate experiments were performed by incubating cells with 10-10 M 125I-IGF I in the presence or absence of 2x10`M unlabeled IGF I for various times. Bound and free radioactivity was separated by rapid filtration through a GF/C filter (Whatman Inc., Clifton, N.J.) preincubated with 1% gelatin, 10% horse serum, and 1 ,uM insulin. Filters were counted in an automated gamma counter with 80% efficiency. To demonstrate that results obtained using cell suspensions were representative of binding to cell monolayers, additional binding experiments were performed using cells grown in 12-well plates. These were quiesced for 48 hours, exposed to 5 ng/ml bFGF in fresh SFM for 24 hours, washed, and then exposed to 10 A representative on-rate experiment is shown in Figure  1A and demonstrates that equilibrium binding was reached after 60 minutes at 20°C. To determine IGF I Figure 1B . Scatchard analysis of the binding data indicated one class of high-affinity binding sites ( Figure 1C ). To determine whether growth factors regulate IGF I receptors on VSMCs, we exposed quiescent RASMs to SFM in the presence or absence of 10 ng/ml PDGF-BB, 5 ng/ml bFGF, and 100 ng/ml Ang II for 24 hours and performed radioligand displacement experiments. As shown in Table 1 Figure 3, 
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